| Nivolumab studied in …STUDIED_INderived200 of 1,426show all (up to 200) |
|---|
| → studied in | NCT01896999Phase 1/Phase 2 · active not recruiting Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 1,426 trials list this drug (493 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02595944Phase 3 · active not recruiting Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03707808Phase 1/Phase 2 · active not recruiting Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic Nivolumab · 1,426 trials list this drug (493 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03811015Phase 3 · active not recruiting Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · 1,426 trials list this drug (493 active) | — | — | Malignant Genitourinary System Neoplasm,Large Cell Neuroendocrine Carcinoma,Sarcomatoid Renal Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04310007Phase 2 · active not recruiting Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04396821Phase 1/Phase 2 · active not recruiting A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors · 1,426 trials list this drug (493 active) | — | — | Malignant Neoplasm,Malignant Gastric Neoplasm,Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04495296Phase 1/Phase 2 · active not recruiting A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors · 1,426 trials list this drug (493 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04751370Phase 2 · active not recruiting Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Rectal Neoplasm,Rectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05675410Phase 3 · recruiting A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · 1,426 trials list this drug (493 active) | — | — | Bladder Urothelial Carcinoma,Muscle Invasive Urethral Urothelial Carcinoma,Muscle Invasive Bladder Urothelial Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · 1,426 trials list this drug (493 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06325683Phase 2 · suspended Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma · 1,426 trials list this drug (493 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07700979Phase 3 · recruiting Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma · 1,426 trials list this drug (493 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · 1,426 trials list this drug (493 active) | — | — | Endometrioid Adenocarcinoma,Endometrial Adenocarcinoma,Endometrial Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07392892Phase 2/Phase 3 · recruiting Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Gastric Neoplasm,Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04123379Phase 2 · active not recruiting Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) · 1,426 trials list this drug (493 active) | — | — | Hepatocellular Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05136196Phase 2 · recruiting BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · 1,426 trials list this drug (493 active) | — | — | Melanoma,Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05715216Phase 2 · active not recruiting EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07401875Phase 1 · recruiting A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) · 1,426 trials list this drug (493 active) | — | — | Malignant Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476326Phase 1 · recruiting Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02940301Phase 2 · active not recruiting Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981899Phase 1/Phase 2 · active not recruiting A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05188118early Phase 1 · completed Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma · 1,426 trials list this drug (493 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047379Phase 1/Phase 2 · recruiting Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis · 1,426 trials list this drug (493 active) | — | — | Melanoma,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07838974Phase 1 · not yet recruiting Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02194738NA · active not recruiting Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) · 1,426 trials list this drug (493 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03816345Phase 1 · recruiting Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO · 1,426 trials list this drug (493 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03899155Phase 2 · recruiting Pan Tumor Rollover Study · 1,426 trials list this drug (493 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05715229Phase 2 · terminated Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561386Phase 3 · recruiting A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06618287Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors · 1,426 trials list this drug (493 active) | — | — | Malignant Breast Neoplasm,Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07031765Phase 1 · active not recruiting Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma · 1,426 trials list this drug (493 active) | — | — | Anaplastic Astrocytoma,Oligoastrocytoma,Ependymoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07219459Phase 2 · recruiting Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07405164Phase 3 · recruiting Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · 1,426 trials list this drug (493 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314169Phase 2 · active not recruiting Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer · 1,426 trials list this drug (493 active) | — | — | Anal Canal Squamous Cell Carcinoma,Anal Canal Carcinoma,Malignant Anal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03258567Phase 2 · recruiting Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas · 1,426 trials list this drug (493 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04079712Phase 2 · active not recruiting Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors · 1,426 trials list this drug (493 active) | — | — | Neuroendocrine Neoplasm,Neuroendocrine Carcinoma,Large Cell Neuroendocrine Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04561206Phase 2 · recruiting Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04810078Phase 3 · active not recruiting A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread · 1,426 trials list this drug (493 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05629546Phase 1 · suspended Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06863311Phase 2 · recruiting Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC · 1,426 trials list this drug (493 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03635892Phase 2 · active not recruiting A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma · 1,426 trials list this drug (493 active) | — | — | Papillary Renal Cell Carcinoma,Renal Cell Carcinoma,Collecting Duct Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04387084Phase 1 · active not recruiting Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy · 1,426 trials list this drug (493 active) | — | — | Malignant Skin Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464759Phase 1/Phase 2 · active not recruiting A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05904080Phase 2 · suspended Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer · 1,426 trials list this drug (493 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03391869Phase 3 · active not recruiting Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma,Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03776487Phase 2 · active not recruiting Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer · 1,426 trials list this drug (493 active) | — | — | Gastric Carcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05048212Phase 2 · recruiting A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases · 1,426 trials list this drug (493 active) | — | — | Brain Neoplasm,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05267626Phase 1/Phase 2 · recruiting Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Cutaneous Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05327686Phase 2 · recruiting Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial · 1,426 trials list this drug (493 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02393625Phase 1 · active not recruiting Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer · 1,426 trials list this drug (493 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03585465Phase 1/Phase 2 · terminated Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors · 1,426 trials list this drug (493 active) | — | — | Childhood Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04902443Phase 1 · recruiting Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV · 1,426 trials list this drug (493 active) | — | — | Kaposi Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06816927Phase 2 · recruiting Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab · 1,426 trials list this drug (493 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07195695Phase 3 · recruiting Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07576725Phase 2 · not yet recruiting Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial · 1,426 trials list this drug (493 active) | — | — | Malignant Solid Neoplasm,Basal Cell Carcinoma,Cutaneous Melanoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03543189Phase 1/Phase 2 · completed Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy · 1,426 trials list this drug (493 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04741997early Phase 1 · recruiting Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04938232Phase 2 · active not recruiting Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL · 1,426 trials list this drug (493 active) | — | — | Hodgkin Lymphoma,Adult Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04940299Phase 2 · active not recruiting Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma · 1,426 trials list this drug (493 active) | — | — | Malignant Solid Neoplasm,Melanoma,Malignant Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05681780Phase 1 · recruiting Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06029270Phase 2 · recruiting Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer · 1,426 trials list this drug (493 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07532902Phase 1 · recruiting A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer · 1,426 trials list this drug (493 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02453620Phase 1 · active not recruiting Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Solid Neoplasm,Breast Adenocarcinoma,Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03233347Phase 2 · active not recruiting Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04462406Phase 2 · active not recruiting Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial · 1,426 trials list this drug (493 active) | — | — | Melanoma,Melanoma of Unknown Primary,Mucosal Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04511013Phase 2 · recruiting A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases · 1,426 trials list this drug (493 active) | — | — | Melanoma,Cutaneous Melanoma,Mucosal Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02530463Phase 2 · active not recruiting Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome · 1,426 trials list this drug (493 active) | — | — | Leukemia,Myelodysplastic Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03307616Phase 2 · active not recruiting Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery · 1,426 trials list this drug (493 active) | — | — | Dedifferentiated Liposarcoma,Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04013542Phase 1 · active not recruiting Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04380545Phase 1/Phase 2 · recruiting Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer · 1,426 trials list this drug (493 active) | — | — | Hepatocellular Carcinoma,Fibrolamellar Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06064097Phase 2 · recruiting A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) · 1,426 trials list this drug (493 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06101134Phase 2 · active not recruiting A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07818018Phase 1/Phase 2 · recruiting A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma · 1,426 trials list this drug (493 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm,Esophageal Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07818070Phase 3 · not yet recruiting A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma · 1,426 trials list this drug (493 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm,Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04162015Phase 1 · active not recruiting A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma · 1,426 trials list this drug (493 active) | — | — | Pleural Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04444921Phase 3 · active not recruiting EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients · 1,426 trials list this drug (493 active) | — | — | Anal Squamous Cell Carcinoma,Anal Basaloid Carcinoma,Anal Canal Cloacogenic Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05845450Phase 2 · recruiting Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) · 1,426 trials list this drug (493 active) | — | — | Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06639607Phase 1/Phase 2 · suspended PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma · 1,426 trials list this drug (493 active) | — | — | Medulloblastoma,Diffuse Intrinsic Pontine Glioma,Diffuse Midline Glioma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02259621Phase 2 · active not recruiting Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · 1,426 trials list this drug (493 active) | — | — | Malignant Genitourinary System Neoplasm,Malignant Solid Neoplasm,Penile Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03233711Phase 3 · active not recruiting Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer · 1,426 trials list this drug (493 active) | — | — | Anal Basaloid Carcinoma,Anal Margin Squamous Cell Carcinoma,Anal Canal Cloacogenic Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03661320Phase 3 · completed A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer · 1,426 trials list this drug (493 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04759586Phase 3 · active not recruiting Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma · 1,426 trials list this drug (493 active) | — | — | Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05111626Phase 3 · terminated Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. · 1,426 trials list this drug (493 active) | — | — | Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05272384Phase 1 · recruiting Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma · 1,426 trials list this drug (493 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03367741Phase 2 · active not recruiting Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer · 1,426 trials list this drug (493 active) | — | — | Endometrial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03414684Phase 2 · completed Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04080804Phase 2 · active not recruiting Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer · 1,426 trials list this drug (493 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06745076Phase 2 · recruiting Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Hodgkin Lymphoma,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07431281Phase 3 · recruiting Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 · 1,426 trials list this drug (493 active) | — | — | Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07541170Phase 3 · recruiting A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07644312Phase 2 · not yet recruiting Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG · 1,426 trials list this drug (493 active) | — | — | Diffuse Intrinsic Pontine Glioma,WHO Grade 3 Glioma,WHO Grade 4 Glioma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07664176Phase 1 · recruiting NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02257528Phase 2 · active not recruiting Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer · 1,426 trials list this drug (493 active) | — | — | Cervical Adenocarcinoma,Cervical Carcinoma,Cervical Adenosquamous Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03122522Phase 2 · active not recruiting A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03906071Phase 3 · completed Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer · 1,426 trials list this drug (493 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04339738Phase 2 · active not recruiting Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma · 1,426 trials list this drug (493 active) | — | — | Skin Angiosarcoma,Skin Radiation-Related Angiosarcoma,Visceral Angiosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05039073Phase 2 · recruiting Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors · 1,426 trials list this drug (493 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05061017Phase 2 · completed Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) · 1,426 trials list this drug (493 active) | — | — | Melanoma,Lung Non-Small Cell Carcinoma,Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05502315Phase 2 · active not recruiting Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07221149Phase 2/Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155061Phase 1 · active not recruiting Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04013854Phase 2 · active not recruiting Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04609046Phase 1 · active not recruiting Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma · 1,426 trials list this drug (493 active) | — | — | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06794229Phase 2 · recruiting Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis · 1,426 trials list this drug (493 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06968988Phase 1 · suspended Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma · 1,426 trials list this drug (493 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07188896Phase 2 · recruiting A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) · 1,426 trials list this drug (493 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05568095Phase 3 · completed A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05677490Phase 3 · recruiting mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma · 1,426 trials list this drug (493 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04562129Phase 2 · active not recruiting IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05721846Phase 1 · completed Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06632327Phase 3 · active not recruiting Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04546399Phase 2 · recruiting A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) · 1,426 trials list this drug (493 active) | — | — | B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03505320Phase 2 · active not recruiting A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer · 1,426 trials list this drug (493 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03743766Phase 2 · completed Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03793166Phase 3 · active not recruiting Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study · 1,426 trials list this drug (493 active) | — | — | Rhabdoid Tumor of the Kidney,Sarcomatoid Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04145115Phase 2 · active not recruiting A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden · 1,426 trials list this drug (493 active) | — | — | Astrocytoma, IDH-Mutant, Grade 4,Diffuse Glioma,Glioblastoma, IDH-Wildtype+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05896839Phase 1/Phase 2 · recruiting Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer · 1,426 trials list this drug (493 active) | — | — | Melanoma,Basal Cell Carcinoma,Skin Squamous Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07551583Phase 2 · recruiting Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL · 1,426 trials list this drug (493 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02224781Phase 3 · active not recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02339571Phase 2/Phase 3 · active not recruiting A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03055013Phase 3 · active not recruiting Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy · 1,426 trials list this drug (493 active) | — | — | Sarcomatoid Renal Cell Carcinoma,Renal Cell Carcinoma,Unclassified Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03595124Phase 2 · active not recruiting A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) · 1,426 trials list this drug (493 active) | — | — | Renal Cell Carcinoma,TFE3-Rearranged Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06683755Phase 1/Phase 2 · recruiting Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05500092Phase 2 · active not recruiting An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05779423Phase 2 · recruiting Cryoablation+Ipilimumab+Nivolumab in Melanoma · 1,426 trials list this drug (493 active) | — | — | Malignant Skin Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04025879Phase 3 · active not recruiting A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03016871Phase 2 · active not recruiting Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL · 1,426 trials list this drug (493 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04039607Phase 3 · completed A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma · 1,426 trials list this drug (493 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011550Phase 2 · suspended Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07430202Phase 1 · not yet recruiting A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07689175Phase 2 · recruiting Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma · 1,426 trials list this drug (493 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02046733Phase 2 · completed Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease · 1,426 trials list this drug (493 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02434081Phase 2 · completed NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03141177Phase 3 · completed A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma · 1,426 trials list this drug (493 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04910347Phase 2 · active not recruiting Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma · 1,426 trials list this drug (493 active) | — | — | Nasopharyngeal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05034536Phase 2 · active not recruiting PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504796Phase 2 · recruiting ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03655002Phase 1 · active not recruiting IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer · 1,426 trials list this drug (493 active) | — | — | Liver Carcinoma,Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03884998Phase 1 · active not recruiting Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Chronic Lymphocytic Leukemia,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04021108Phase 2 · active not recruiting Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02879695Phase 1 · active not recruiting Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia · 1,426 trials list this drug (493 active) | — | — | B Acute Lymphoblastic Leukemia,Mixed Phenotype Acute Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03274258Phase 2 · terminated Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma · 1,426 trials list this drug (493 active) | — | — | Renal Cell Carcinoma,Kidney Medullary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03355976Phase 2 · active not recruiting BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas · 1,426 trials list this drug (493 active) | — | — | Primary Peritoneal Carcinoma,Clear Cell Adenocarcinoma,Malignant Fallopian Tube Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04008030Phase 3 · active not recruiting A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) · 1,426 trials list this drug (493 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04572451Phase 1 · active not recruiting Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma · 1,426 trials list this drug (493 active) | — | — | Neoplasm,Neoplasm by Site,Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04933903Phase 2 · recruiting BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab · 1,426 trials list this drug (493 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07770100Phase 2 · not yet recruiting Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) · 1,426 trials list this drug (493 active) | — | — | Malignant Head and Neck Neoplasm,Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03025256Phase 1 · active not recruiting Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease · 1,426 trials list this drug (493 active) | — | — | Melanocytoma,Melanoma,Malignant Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04725474Phase 1/Phase 2 · active not recruiting First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) · 1,426 trials list this drug (493 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05317858Phase 3 · recruiting Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets · 1,426 trials list this drug (493 active) | — | — | Brain Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05361720Phase 2 · recruiting Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study · 1,426 trials list this drug (493 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06059547Phase 2 · completed Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer · 1,426 trials list this drug (493 active) | — | — | Adult Solid Neoplasm,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07246863Phase 2 · recruiting Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC · 1,426 trials list this drug (493 active) | — | — | Adult Solid Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07276373Phase 1/Phase 2 · recruiting Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies · 1,426 trials list this drug (493 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03173950Phase 2 · terminated Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers · 1,426 trials list this drug (493 active) | — | — | Choroid Plexus Neoplasm,Medulloblastoma,Ependymoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03728361Phase 2 · completed Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Lung Neoplasm,Neuroendocrine Carcinoma,Neuroendocrine Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04929041Phase 2/Phase 3 · active not recruiting Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative · 1,426 trials list this drug (493 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma,Lung Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06743126Phase 3 · recruiting SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07620574Phase 3 · enrolling by invitation Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study · 1,426 trials list this drug (493 active) | — | — | Malignant Neoplasm,Hepatocellular Carcinoma,Pancreatic Neuroendocrine Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03463408early Phase 1 · completed Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma · 1,426 trials list this drug (493 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03646617Phase 2 · active not recruiting Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04840589Phase 1 · suspended Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors · 1,426 trials list this drug (493 active) | — | — | Malignant Solid Neoplasm,Ovarian Carcinoma,Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05919264Phase 1/Phase 2 · recruiting FOG-001 in Locally Advanced or Metastatic Solid Tumors · 1,426 trials list this drug (493 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Adamantinomatous Craniopharyngioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07166406Phase 3 · recruiting Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial · 1,426 trials list this drug (493 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03502733Phase 1 · active not recruiting Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma · 1,426 trials list this drug (493 active) | — | — | Lymphoma,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03843294Phase 1 · active not recruiting Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma · 1,426 trials list this drug (493 active) | — | — | Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06284564Phase 2 · active not recruiting A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) · 1,426 trials list this drug (493 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02978625Phase 2 · active not recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers · 1,426 trials list this drug (493 active) | — | — | Anaplastic Large Cell Lymphoma,Anaplastic Large Cell Lymphoma, ALK-Negative,Anaplastic Large Cell Lymphoma, ALK-Positive+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05407675Phase 1/Phase 2 · completed A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors · 1,426 trials list this drug (493 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03203473Phase 2 · active not recruiting Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) · 1,426 trials list this drug (493 active) | — | — | Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04126070Phase 2 · active not recruiting Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors · 1,426 trials list this drug (493 active) | — | — | Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06250335Phase 2 · active not recruiting Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07187869Phase 1 · recruiting Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study · 1,426 trials list this drug (493 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07420439Phase 2 · not yet recruiting Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02955290Phase 1/Phase 2 · active not recruiting CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Lung Neoplasm,Head and Neck Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05262556Phase 1 · completed NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas · 1,426 trials list this drug (493 active) | — | — | Digestive System Neuroendocrine Neoplasm,Mixed Neuroendocrine Non-Neuroendocrine Neoplasm,Digestive System Neuroendocrine Tumor+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04099251Phase 3 · active not recruiting Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma · 1,426 trials list this drug (493 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06534983Phase 2 · active not recruiting A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07444619Phase 1 · recruiting A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas · 1,426 trials list this drug (493 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05176483Phase 1 · recruiting Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors · 1,426 trials list this drug (493 active) | — | — | Solid Neoplasm,Head and Neck Squamous Cell Carcinoma,Hepatocellular Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05647265Phase 2 · recruiting Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma · 1,426 trials list this drug (493 active) | — | — | Pleural Biphasic Mesothelioma,Pleural Sarcomatoid Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03143270early Phase 1 · completed A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03907488Phase 3 · active not recruiting Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma · 1,426 trials list this drug (493 active) | — | — | Classic Hodgkin Lymphoma,Lymphocyte-Rich Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04887870Phase 2/Phase 3 · completed Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study · 1,426 trials list this drug (493 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05111574Phase 2 · active not recruiting Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery · 1,426 trials list this drug (493 active) | — | — | Head and Neck Mucosal Melanoma,Vulvar Melanoma,Esophageal Melanoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05199285Phase 2 · terminated A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab · 1,426 trials list this drug (493 active) | — | — | Hepatocellular Carcinoma,BCLC Stage B Hepatocellular Carcinoma,BCLC Stage C Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06622941Phase 2 · recruiting Study to ONO-4538 in Patients With Rhabdoid Tumor · 1,426 trials list this drug (493 active) | — | — | Rhabdoid Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03662074Phase 2 · terminated Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer · 1,426 trials list this drug (493 active) | — | — | Malignant Lung Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03383458Phase 3 · active not recruiting A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation · 1,426 trials list this drug (493 active) | — | — | Hepatocellular Carcinoma,Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03604978Phase 1/Phase 2 · active not recruiting Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma · 1,426 trials list this drug (493 active) | — | — | Meningioma,Grade 2 Meningioma,Grade 3 Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03816332Phase 1 · active not recruiting Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers · 1,426 trials list this drug (493 active) | — | — | Melanoma,Basal Cell Carcinoma,Skin Squamous Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914300Phase 2 · active not recruiting Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer · 1,426 trials list this drug (493 active) | — | — | Thyroid Gland Follicular Carcinoma,Thyroid Gland Oncocytic Carcinoma,Differentiated Thyroid Gland Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04652960Phase 1 · active not recruiting Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome · 1,426 trials list this drug (493 active) | — | — | Mycosis Fungoides and Sezary Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04912765Phase 2 · recruiting Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC · 1,426 trials list this drug (493 active) | — | — | Hepatocellular Carcinoma,Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06866262Phase 1/Phase 2 · recruiting Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial · 1,426 trials list this drug (493 active) | — | — | Sarcomatoid Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |